Allergan
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Allergan sits in the top decile of US sponsors by registered trial count (#114 of 15,742 sponsors by registered trial count).
Allergan: 314 sponsored US clinical trials, none currently recruiting.
Allergan sponsors 314 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 278 completed. 142 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ocular Hypertension, with 9 trials.
Top-decile sponsor footprint
Allergan ranks in the top decile of sponsors by registered trial count (#114 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
278 of 313 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
314 total, page 5 of 7
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
NCT01089062
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
NCT01089751
Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence
NCT01064882
Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
NCT01027650
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
NCT00915525
Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System
NCT01080209
Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema
NCT01042678
Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®
NCT01170884
Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis
NCT00958035
Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function
NCT00972374
Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution
NCT01001195
Safety and Efficacy of Two Artificial Tears in Dry Eye Subjects
NCT01010282
Study of Cyclosporine in Post-LASIK Patients
NCT00991458
Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects
NCT00986401
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
NCT00910845
Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma
NCT00995904
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
NCT00910520
Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation
NCT00978042
A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia
NCT00894517
Safety and Tolerability of Artificial Tears in Dry Eye Subjects
NCT00932477
Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin
NCT00907426
Trospium Chloride XR in Obese Female Patients With Overactive Bladder
NCT00932022
Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
NCT00884585
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
NCT00863551
A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms
NCT00874887
Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines
NCT00856414
A Natural History Study of Patients With Dry Eye
NCT00833235
Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
NCT00809848
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
NCT00876447
Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema
NCT00799227
A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin
NCT00834171
CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy
NCT00836017
Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%
NCT00827255
An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects
NCT00811564
Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris
NCT00835198
Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris
NCT00834210
Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow
NCT00811850
Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
NCT00791323
Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)
NCT00775411
Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy
NCT00693485
Efficacy and Acceptability of Two Lubricant Eye Drops
NCT00756678
Phase 3 Study of MAP0004 in Adult Migraineurs
NCT00623636
An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa
NCT00661479
Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects
NCT00735449
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
NCT00658619
Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear
NCT00691197
A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
NCT00518089
Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia
NCT00564681
Surveillance of Ocular Surface Flora (SURFACE)
NCT00621933
Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension
NCT00541242
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 85 |
| Phase 3 | 91 |
| Phase 4 | 51 |
Therapeutic Areas
How the Allergan archive is shaped
314 indexed studies, none listed as recruiting (0% open); 278 completed (89%).
Phase mix: 142 late (III/IV) vs 114 early (I/II) (balanced across stages).
Top condition: Ocular Hypertension (9 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Allergan: archived-pipeline peers nationwide
Peers matched on 314 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Allergan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 314 archived trials
- University of Arkansas · 318 trials · 12% recruiting
- Rush University Medical Center · 320 trials · 17% recruiting
- Celgene · 308 trials · 4% recruiting
- Jonsson Comprehensive Cancer Center · 321 trials · 19% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Allergan page
314 registered trials is a research-attention snapshot, not an endorsement of Allergan or any single study.
- None of Allergan's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Ocular Hypertension is the condition Allergan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ocular Hypertension trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Allergan pipeline card: 314 registered trials from official public datasets.Report a data error.